<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617600</url>
  </required_header>
  <id_info>
    <org_study_id>14422019496708</org_study_id>
    <nct_id>NCT04617600</nct_id>
  </id_info>
  <brief_title>Survival Rate After TheraCal PT Pulpotomy Versus MTA Pulpotomy in Children With Vital Primary Molars.</brief_title>
  <official_title>Survival Rate After TheraCal PT Pulpotomy Versus MTA Pulpotomy in Children With Vital Primary Molars: A Randomized Controlled Pilot Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the effect of TheraCal PT pulpotomy versus MTA pulpotomy on&#xD;
      the survival rate of cariously exposed vital primary molars.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      for both interventions ,&#xD;
&#xD;
        1. Informed consent from participating parents.&#xD;
&#xD;
        2. Baseline records photographs, percussion test, periapical radiograph and personal data&#xD;
           collection.&#xD;
&#xD;
        3. Allocation (concealed by withdrawing a sealed opaque envelope containing eight times&#xD;
           folded paper containing the type of dressing material that will be used then writing&#xD;
           patient name and I.D. on it and will be opened after performing the access cavity).&#xD;
&#xD;
        4. Diagnostic chart with personal, medical and dental history will be filled.&#xD;
&#xD;
        5. Clinical examination will be performed to assess the clinical inclusion criteria.&#xD;
           (Pulpal and periapical diagnosis is established after clinical examination).&#xD;
&#xD;
        6. Preoperative and Postoperative photographs will be taken.&#xD;
&#xD;
        7. The radiographic examination will be performed by taking periapical x-ray using&#xD;
           (parallel technique) through machine to assess the inclusion criteria. The preoperative&#xD;
           radiograph will serve as a reference for the follow-up radiographs. Standardization of&#xD;
           the technique to avoid any distortion in the vertical dimension and to provide&#xD;
           reproducible images using x-ray holding device.&#xD;
&#xD;
        8. Preoperative and postoperative radiograph will be taken by parallel technique using&#xD;
           extension cone paralleling (XCP) film holder.&#xD;
&#xD;
        9. Administration of inferior alveolar nerve block (Septodont, Scandonest® 2% L Mepivacaine&#xD;
           hydrochloride (HCl). 2% and Levonordefrin 1:20,000 Injection, U.S.P.) at the side of the&#xD;
           affected tooth.&#xD;
&#xD;
       10. Application of rubber dam for isolation, then a standardized pulpotomy procedure will be&#xD;
           performed using a large sterile round end bur in a high-speed handpiece with copious&#xD;
           irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level.&#xD;
           Hemostasis will be achieved by the application of a wet cotton pellet.&#xD;
&#xD;
      Children will then be allocated into either one of the groups alternatively depending on the&#xD;
      pulpotomy medicament used as follows:&#xD;
&#xD;
        -  Group I (Experimental group) TheraCal PT pulpotomy.&#xD;
&#xD;
        -  Group II (Control group) MTA pulpotomy.&#xD;
&#xD;
      Group I (Experimental group) TheraCal PT:&#xD;
&#xD;
        1. After complete hemostasis, TheraCal PT (BISCO Dental Products, Schamberg illinois (IL),&#xD;
           U.S.A.) will be applied according to the manufacturer's instructions and gently placed&#xD;
           over the pulp stumps to a thickness of 2mm then the rest of the pulp chamber will be&#xD;
           filled with glass ionomer cement.&#xD;
&#xD;
        2. Tooth will then be restored with stainless steel crown.&#xD;
&#xD;
      Group II (Control group) MTA pulpotomy:&#xD;
&#xD;
        1. After complete hemostasis, MTA+ Curamed (ul. Kwiatkowskiego 1, 37-450 stylosa Wola,&#xD;
           Polka) will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix.&#xD;
           This mix will be placed over the radicular pulp with the help of a suitable sterile&#xD;
           amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a&#xD;
           moistened cotton pellet, followed by application of glass ionomer cement.&#xD;
&#xD;
        2. Tooth will then be restored with stainless steel crown.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate (Absence of spontaneous pain)</measure>
    <time_frame>&quot;3 months&quot;</time_frame>
    <description>Binary outcome measured with direct questioning to the patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival rate (Absence of spontaneous pain)</measure>
    <time_frame>&quot;6 months&quot;</time_frame>
    <description>Binary outcome measured with direct questioning to the patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival rate (Absence of swelling)</measure>
    <time_frame>&quot;3 months&quot;</time_frame>
    <description>Binary outcome measured visually by intraoral/extraoral examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival rate (Absence of swelling)</measure>
    <time_frame>&quot;6 months&quot;</time_frame>
    <description>Binary outcome measured visually by intraoral/extraoral examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of periapical radiolucency or absence of internal/external root resorption</measure>
    <time_frame>&quot;6 months&quot;</time_frame>
    <description>Binary outcome detected with periapical x-ray by parallel technique using XCP film holder (Super Bite, Hawe Neos DentalSA, Switzerland).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time lapse till final restoration performed.</measure>
    <time_frame>&quot;During procedure&quot;.</time_frame>
    <description>Continuous outcome measured with a Stopwatch in minutes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Reversible Pulpitis</condition>
  <arm_group>
    <arm_group_label>Mineral trioxide aggregate (MTA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TheraCal PT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTA</intervention_name>
    <description>Survival rate using MTA in cariously exposed vital primary molars</description>
    <arm_group_label>Mineral trioxide aggregate (MTA)</arm_group_label>
    <other_name>Mineral trioxide aggregate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TheraCal PT</intervention_name>
    <description>Survival rate using TheraCal PT in cariously exposed vital primary molars</description>
    <arm_group_label>TheraCal PT</arm_group_label>
    <other_name>TheraCal PT®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 4 to 7 years , in good general health and mentally free.&#xD;
&#xD;
          -  The parents provided written informed consent.&#xD;
&#xD;
          -  Cariously exposed primary molars with reversible pulpitis.&#xD;
&#xD;
          -  Teeth should be vital.&#xD;
&#xD;
          -  Restorable teeth.&#xD;
&#xD;
          -  Hemostasis achieved after complete pulpotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With systemic disease.&#xD;
&#xD;
          -  Physical or mental disability.&#xD;
&#xD;
          -  Unable to attend follow-up visits.&#xD;
&#xD;
          -  Refusal of participation.&#xD;
&#xD;
          -  Previously accessed teeth.&#xD;
&#xD;
          -  History of spontaneous or prolonged pain.&#xD;
&#xD;
          -  Swelling, tenderness to percussion or palpation, or pathological mobility.&#xD;
&#xD;
          -  Pre-operative radiographic pathology such as resorption(internal or&#xD;
             external),per-radicular or furcation radiolucency.&#xD;
&#xD;
          -  Haemorrhage control is unachievable after pulpotomy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Reem Mohamed Gaber</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

